AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: MiR-451a represses the AKT/mTOR signaling pathway [70], and AKT regulates SOX9 expression [71] to maintain the imatinib-resistant phenotype of CML CD34+ cells [72].